Utah 2025 Regular Session

Utah House Bill HB0543

Introduced
2/24/25  

Caption

Controlled Substance Licensing Amendments

Impact

The implications of HB 543 are substantial, particularly in how they govern the prescribing of controlled substances. The bill mandates that prescribers offer to prescribe an opiate antagonist to patients receiving high doses of opiates, as well as engage in a thorough discussion with patients about the risks associated with these medications. With this requirement, the bill aims to enhance patient awareness and reduce the potential for addiction, thereby addressing the ongoing opioid crisis. Additionally, it includes provisions for the creation of electronic prescriptions to further streamline and regulate the process of prescribing controlled substances.

Summary

House Bill 543, known as the Controlled Substance Licensing Amendments, seeks to amend various provisions related to the licensure and regulation of controlled substances in the state. A significant component of the bill is the introduction of controlled substance certification for practitioners who wish to prescribe, dispense, or administer controlled substances. The bill stipulates that beginning July 1, 2025, practitioners must obtain this certification to distribute or dispense controlled substances, ensuring that they meet the necessary qualifications and training requirements established by the state.

Contention

Debate surrounding HB 543 has surfaced regarding concerns about the potential overreach into the longstanding physician-patient relationship. Critics argue that the requirement for prescribers to follow strict guidelines may hinder the movement of physicians in making individualized care decisions based on the context of their patient's needs. Furthermore, some members of the legislative discussions have pointed out that while the bill aims to combat addiction, the number of regulatory requirements could inadvertently create barriers for healthcare providers, especially those in rural or underserved areas who may find compliance challenging.

Companion Bills

No companion bills found.

Similar Bills

KS HB2218

Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.

KY HB389

AN ACT relating to prescription drugs.

TX HB3301

Relating to the regulation of controlled substances and the establishment of an electronic system for monitoring controlled substances; providing criminal penalties; authorizing a fee.

TX HB3714

Relating to the regulation of controlled substances and the establishment of an electronic system for monitoring controlled substances; providing criminal penalties.

VA HB2775

Hemp product; clarifies definition.

RI H5615

Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.

KS SB292

Prohibiting the transfer of hemp-derived cannabinoid products to any person under the age of 21, establishing packaging and labeling requirements for such products and amending the definition of industrial hemp and hemp products.

KS HB2366

Expanding the scope of practice of naturopathic doctors, specifying continuing education requirements, increasing the required amount of professional liability insurance and modifying certain provisions relating to the licensure and regulations of naturopathic doctors.